RESEARCH ARTICLE

Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis

Jirui Bi¹☯, Jin Yang¹☯, Ying Wang¹, Cijiang Yao², Jing Mei¹, Ying Liu², Jiyu Cao³, Youjin Lu¹*

¹ Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, China, ² School of Public Health, Anhui Medical University, Hefei, China, ³ The Teaching Center for Preventive Medicine, School of Public Health, Anhui Medical University, Hefei, China

☯ These authors contributed equally to this work.
* luyougolden@hotmail.com

Abstract

Background

Adjunctive corticosteroids therapy is an attractive option for community-acquired pneumonia (CAP) treatment. However, the effectiveness of adjunctive corticosteroids on mortality of CAP remains inconsistent, especially in severe CAP. We performed a meta-analysis to evaluate the efficacy and safety of adjunctive corticosteroids in severe CAP patients.

Methods

Three databases of PubMed, EMBASE and Cochrane Library were searched for related studies published in English up to December, 2015. Randomized controlled trials (RCTs) of corticosteroids in hospitalized adults with severe CAP were included. Meta-analysis was performed by a random-effect model with STATA 11.0 software. We estimated the summary risk ratios (RRs) or effect size (ES) with its corresponding 95% confidence interval (95%CI) to assess the outcomes.

Results

We included 8 RCTs enrolling 528 severe CAP patients. Adjunctive corticosteroids significantly reduced all-cause mortality (RR = 0.46, 95%CI: 0.28 to 0.77, p = 0.003), risk of adult respiratory distress syndrome (ARDS) (RR = 0.23, 95%CI: 0.07 to 0.80, p = 0.02) and need for mechanical ventilation (RR = 0.50, 95%CI: 0.27 to 0.92, p = 0.026). Adjunctive corticosteroids did not increase frequency of hyperglycemia requiring treatment (RR = 1.03, 95% CI: 0.61 to 1.72, p = 0.91) or gastrointestinal hemorrhage (RR = 0.66, 95%CI: 0.19 to 2.31, p = 0.52). In subgroup analysis by duration of corticosteroids, we found that prolonged...
corticosteroids therapy significantly reduced all-cause mortality (RR = 0.41, 95%CI: 0.20 to 0.83, p = 0.01) and length of hospital stay (−4.76 days, 95% CI:-8.13 to -1.40, p = 0.006).

Conclusions
Results from this meta-analysis suggested that adjunctive corticosteroids therapy was safe and beneficial for severe CAP. In addition, prolonged corticosteroids therapy was more effective. These results should be confirmed by adequately powered studies in the future.

Introduction
Community-acquired pneumonia (CAP) is a common and serious infectious disease accompanied with high morbidity and mortality [1], about 20% of CAP adult patients acquire hospitalization, and has a mortality of 30–50% [2]. Furthermore, severe CAP occurs in approximately 10% of hospitalized patients with CAP, and has a higher mortality [3]. Despite recent advances in antimicrobial therapy and life-support measures, the mortality of severe CAP has not declined yet [4, 5]. Therefore, potential therapies of severe CAP should be explored.

Pneumonia is characterized by lung inflammation, with fluid filling the alveoli and preventing adequate oxygenation of the body [6]. During infectious pneumonia, an excessive release of circulating inflammatory cytokines, such as interleukin (IL)-10, IL-8 and IL-6 that acted as acute phase markers, would cause pulmonary dysfunction [7]. A recent study demonstrated that the raised levels of IL-6 and IL-10 were related with a high mortality in CAP, especially in severe CAP [8] which could potentially increase the incidences of sepsis, lung injury and acute respiratory distress syndrome (ARDS) [9]. Therefore, active and effective prevention of inflammatory deterioration is vital to severe CAP treatment.

Currently, corticosteroids are the most potent anti-inflammatory drugs. The therapeutic mechanism of corticosteroids might base on attenuating the action of many cytokines that participated in the inflammatory reaction associating severe CAP [10]. In addition, with the proposition of critical illness-related corticosteroid insufficiency (CIRCI), corticosteroids replacement therapy has been gradually accepted in critical illness, such as septic shock and ARDS [11]. Salluh et al. found that the most of patients with severe CAP could have relative adrenal insufficiency [12]. Another study also demonstrated that the reduction of baseline cortisol level could exacerbate the severity and outcomes of severe CAP [13]. Up to date, many physicians have been using corticosteroids for severe CAP patients though the best usage regimens of corticosteroids were unclear [14]. Taken together, these facts indicated corticosteroids were of potential benefit in severe CAP.

In recent decades, adjunctive corticosteroids in severe CAP has been assessed in many randomized controlled trials (RCTs) [15–28]. However, the results of previous RCTs were inconsistent, and meta-analyses conducted to evaluate those RCTs had also failed to establish a complete agreement [29–37]. Recent meta-analyses conducted by Horita et al. [35] and Siemieniuk et al. [36] revealed that adjunctive corticosteroids statistically reduced the mortality of severe CAP. However, Wan et al. [37] proved that adjunctive corticosteroids was not associated with decreased mortality of patients with severe CAP. Therefore, we believed a meta-analysis, which depending on the best updating available evidence, was required. The aim of this study was to evaluate the efficacy and safety of adjunctive corticosteroids in the management of adult hospitalized patients with severe CAP.
Materials and Methods

This study was conducted adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Search strategy

We conducted a literature search in PubMed, EMBASE and Cochrane Library up to December, 2015. The search strategy included the following key words: “(severe community acquired pneumonia OR severe CAP) AND (corticosteroids OR corticotherapy OR steroids OR dexamethasone OR methylprednisolone OR prednisone OR cortisone OR hydrocortisone OR prednisolone)”. The search was limited to studies written in English and those utilizing RCT subjects. The detailed search strategy was available in S3 File. To ensure a comprehensive literature search, we also examined reference lists from included articles.

Selection criteria

In this meta-analysis, we included studies that met the following eligibility criteria: (1) population: aged 18 years or older; (2) study design: RCTs (including quasi-RCTs), English language; (3) intervention: corticosteroids adjunctive therapy in severe CAP; (4) control intervention: placebo or standard treatment; (5) any types, any doses, and any durations of systemic corticosteroids were allowed; (6) primary outcome: all-cause mortality; (7) secondary outcomes: length of ICU stay, length of hospital stay, ARDS, need for mechanical ventilation and adverse effects. Articles were excluded based on the following criteria: (1) studies only had abstracts; (2) studies enrolled pediatric patients, nosocomial pneumonia patients or specified pathogens.

Data Abstraction

Two reviewers extracted data independently and resolved disagreements by a consensus. Data was extracted from those included studies according to the pre-designed form: first author, year of publication, study design, location, number of patients, participant demographics, duration of corticosteroids treatment, doses of corticosteroids, evaluation criteria of severe CAP and outcomes. We contacted the authors of the included studies by E-mail if further study details were needed.

In previous meta-analyses, severe CAP was defined according to common criteria: CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, and age 65 years or older) score of 2 or greater [38], Pneumonia Severity Index score (PSI) of IV or V [39], the American Thoracic Society (ATS) [40], and the British Thoracic Society criteria (BTS) [41]. The four proxies for “severe” CAP have advantages and disadvantages in clinical practice [42]. In addition, the two prediction tools SMART-COP [43] and predisposition, insult, response, and organ dysfunction (PIRO) [44] which are required further validation have similar sensitivity and specificity with ATS or outperform ATS [45]. In this study, we selected severe cases depended on the above tools, authors’ classification of severe CAP when objective scoring was not available and limited to ICU cases.

Data Synthesis and Statistical Analysis

If both per-protocol-analysis and intention-to-treat (ITT) analysis were conducted, ITT manner was chosen. Throughout the meta-analysis, we calculated risk ratios (RRs) and 95% confidence interval (CI) across all studies using a Mantel-Haenszel random-effects model for dichotomous outcomes and the effect size (ES) using an inverse-variance random effects model [46]. Heterogeneity was evaluated using the I² test statistic and classified as no...
heterogeneity ($I^2 = 0$), the least ($\leq 25\%$), mild ($25\% - 50\%$), moderate ($50\% - 75\%$), and strong ($\geq 75\%$) [47]. A sensitivity analysis was implemented by the sequential dropping of each study. The potential publication bias was assessed via funnel plots [48]. A $p < 0.05$ was considered statistically significant. All statistical analyses were undertaken in STATA 11.0 software (Stata Corporation, College Station, TX).

**Results**

**Trial flow**

Our study design produced 1679 studies. Based on the inclusion and exclusion criteria, 1672 studies were excluded. Finally, 8 RCTs were included for meta-analysis [17–19, 21, 22, 24, 26, 28], and a PRISMA flow diagram of selection process for studies was shown in Fig 1. Among included RCTs, one study included mild to severe CAP patients, we selected the severe CAP cases which were defined by PSI of IV or V [21]. A study by El-Ghamrawy [19] which was not found in Search Databases, we obtained data from previous review [36].

**Study characteristics**

Table 1 described the main characteristics of included studies, including 286 patients in the corticosteroids group and 242 patients in the control group. The different types of corticosteroids including hydrocortisone, methyl-prednisolone, dexamethasone and prednisolone. The durations of corticosteroids treatment ranged from 1 to 9 days. Various scoring systems, authors’ classification of severe CAP and ICU cases were used to define severe CAP. Detailed extractive information from included studies were presented in Tables 1 and 2.

**Quality Assessment**

Two authors (Jirui Bi and Jin Yang) carried out data extraction and assessed the risk of bias independently, any conflicts were resolved with group consensus. The Cochrane Collaboration’s Risk of Bias Tool [49] was used to assess the quality of all included RCTs (Table 3).

**Primary Outcome**

The main results for binary outcomes (Mantel-Haenszel method, random effect model) were presented in Table 4.

**All-Cause Mortality**

The pooled results of all-cause mortality was significantly reduced by the use of corticosteroids (8 trials, RR = 0.46, 95%CI: 0.28 to 0.77, $p = 0.003$, $I^2 = 0\%$) (Fig 2).

Subgroup analysis was performed by duration of corticosteroids treatment. Corticosteroids therapy reduced all-cause mortality in severe CAP, but the best corticosteroids duration for severe CAP was not fully clear. Our analysis suggested that prolonged use of corticosteroids ($> 5$ days) was more effective for severe CAP (RR = 0.41, 95%CI: 0.21 to 0.82, $p = 0.01$; $I^2 = 15.1\%$) (Fig 3). There was no statistically significant difference in short course of corticosteroids ($\leq 5$ days) (2 trials; RR = 0.59, 95%CI: 0.24 to 1.43, $p = 0.241$; $I^2 = 0\%$).

**Secondary outcomes**

**Length of hospital stay.** 5 RCTs reported the difference of length of hospital stay in days. Based on these data, we found strong heterogeneity ($I^2 = 90.6\%$) in the primary analysis of
hospital stay days (Fig 4a). In subgroup analysis by the treatment duration of corticosteroids, the result was −5.79 days (95% CI: −8.17 to −2.31, \(I^2 = 61.4\%\)), there was also moderate heterogeneity. We performed a sensitivity analysis excluding Nafae, and the final result was −4.76 days (95% CI: −8.13 to −1.40, \(p = 0.006; I^2 = 43.4\%\), \(p\) for heterogeneity = 0.17) (Fig 4b).
Table 1. Characteristics of included randomized controlled trials in the meta-analysis.

| Study, year | Location | Study design | Sample sizes | Mean age (y) | Severe criterion | Corticosteroids used | Outcome |
|-------------|----------|--------------|--------------|--------------|------------------|----------------------|---------|
| Marik [17], 1993 | USA | DB RCT | 14/16 | 34 | ICU, BTS | Hydrocortisone, 10 mg/kg, 1d | Mortality |
| Confalonieri [18], 2005 | Italy | DB RCT | 23/23 | 64 | ICU, ATS | Hydrocortisone, 240 mg/d, 7d | Hospital mortality |
| El-Ghamray [19], 2006 | Saudi Arabia | DB RCT | 17/17 | 61.8 | ICU, ATS | Hydrocortisone 200 mg IV bolus followed by 10 mg/h for 7d | Hospital mortality |
| Snijders [21], 2010 | Netherlands | DB RCT | 48/45 | 63 | PSI | Prednisolone, 40 mg/d, 7d | 30-d mortality |
| Sabry [24], 2011 | Egypt | DB RCT | 40/40 | 62 | ATS | Hydrocortisone, 300mg/d, 7d | ICU mortality |
| Fernandez-Serrano [22], 2011 | Spain | DB RCT | 23/22 | 63 | PSI | Methylprednisolone, 620mg, 9d | Mortality |
| Nafae [26], 2013 | Egypt | Open-label RCT | 60/20 | 49 | PSI | Hydrocortisone, 200mg (at day 1) and the 10mg/h IV for 7d | Mortality |
| Torres [28], 2015 | Spain | DB RCT | 61/59 | 65.3 | ICU, ATS | Methylprednisolone, 0.5mg/Kg, 2/d, 5d | Hospital mortality |

DB: double-blind; RCT: randomized controlled trial; ATS: American Thoracic Society; BTS: British Thoracic Society; PSI: Pneumonia Severity Index; ICU: intensive care unit; IV: intravenous. Severe community-acquired pneumonia is defined as PSI of IV or V, CURB-65 score ≥2; Meeting 1 of the ATS 1993 criteria; ATS 2001 rule where 1 major or 2 minor criteria are satisfied; ATS-IDSA 2007 rule where 1 major or 3 minor criteria are satisfied; BTS ≥3. n: the number of patients in the corticosteroids group, N: the number of patients in the control group.

Table 2. Outcome data per study.

| Study, Year | Sample size (n/N) | Mortality (n/N) | Treatment duration (n/N) | Length of hospital stay, d (n/N) | Length of ICU stay, d (n/N) | Developed ARDS (n/N) | Required mechanical ventilation (n/N) | Hyperglycemia requiring treatment (n/N) | Gastrointestinal bleeding (n/N) |
|-------------|------------------|-----------------|-------------------------|-----------------|-----------------|-----------------|----------------|-------------------------------|-----------------|
| Marik, 1993 | 14/16            | 1/3             | ≤5d                     | -               | 4.30±3.80/4.60±5.90 | -               | 2/4             | -                             | -               |
| Confalonieri, 2005 | 23/23 | 0/8             | >5d                     | 22.25±10.75/29.25±17.25 | 14.25±7.25/21.00±10.25 | 0/4             | -               | -                             | 1/1             |
| El-Ghamray, 2006 | 17/17 | 3/6             | >5d                     | -               | -               | 0/3             | -               | -                             | -               |
| Snijders, 2010 | 48/45            | 4/3             | >5d                     | -               | -               | -               | -               | -                             | -               |
| Sabry, 2011 | 40/40            | 2/6             | >5d                     | -               | -               | 2/6             | -               | -                             | -               |
| Fernandez-Serrano, 2011 | 23/22 | 1/1             | >5d                     | 10.00±2.96/12±6.67 | 6.50±2.69/10.50±13.52 | -               | 1/5             | 1/0                           | 1/1             |
| Nafae, 2013 | 60/20            | 4/6             | >5d                     | 9.27±2.40/16.50±2.24 | 3.10±4.90/6.30±8.20 | -               | 8/5             | 19/8                          | 1/1             |
| Torres, 2015 | 61/59            | 6/9             | ≤5d                     | 11.00±3.81/10.50±2.19 | 5.00±3.70/6.00±2.96 | -               | 5/9             | 11/7                          | 0/1             |

ICU: intensive care unit; ARDS: acute respiratory distress syndrome; n: the number of patients in the corticosteroids group, N: the number of patients in the control group.

Table 3. Summarizes the risk of bias.

| Author                | Randomization method | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias | Overall risk |
|-----------------------|-----------------------|------------------------|----------------------------------------|-------------------------------|------------------------|---------------------|-----------|-------------|
| Marik                 | Low                   | Low                    | Low                                    | Low                           | Low                    | Low                 | Unclear   | Low         |
| Confalonieri          | Low                   | Low                    | Low                                    | Low                           | Low                    | Low                 | Unclear   | Low         |
| El-Ghamray            | Low                   | Unclear                | Unclear                                | Low                           | Low                    | Low                 | Low       | Low         |
| Snijders              | Low                   | Low                    | Low                                    | Low                           | Low                    | Low                 | Low       | Low         |
| Sabry                 | Low                   | Low                    | Low                                    | Low                           | Low                    | Low                 | Low       | Low         |
| Fernandez-Serrano     | Low                   | Unclear                | Low                                    | Low                           | Unclear                | Low                 | Low       | Low         |
| Nafae                 | Unclear               | Low                    | Unclear                                | Unclear                       | Unclear                | Low                 | Unclear   | High        |
| Torres                | Low                   | Unclear                | Low                                    | Low                           | Low                    | Low                 | Low       | Low         |

doi:10.1371/journal.pone.0165942.1002
Length of ICU stay. Based on the data of 4 RCTs, we found that corticosteroids did not significantly decrease the length of ICU stay (−1.84 days, 95% CI: -4.23 to 0.56, p = 0.13, $I^2 = 38.6\%$) (Fig 5).

Acute Respiratory Distress Syndrome. 3 RCTs evaluated the risk of ARDS in patients. We found a statistically significant reduction in the risk of ARDS treated with corticosteroids (RR = 0.23, 95% CI: 0.07 to 0.80, p = 0.02; $I^2 = 0\%$) (Fig 6).

Mechanical ventilation. 4 RCTs revealed a reduction in the need for mechanical ventilation in patients treated with corticosteroids (RR = 0.50, 95% CI: 0.27 to 0.92, p = 0.026; $I^2 = 0\%$) (Fig 6).

Adverse effects. The adverse effects of corticosteroids therapy mainly included hyperglycemia and gastrointestinal hemorrhage. The results of the analysis showed that systemic corticosteroids had no effects on hyperglycemia (3 trials; RR = 1.03, 95% CI: 0.61 to 1.72, p = 0.91; $I^2 = 0\%$) and gastrointestinal hemorrhage (5 trials; RR = 0.66, 95% CI: 0.19 to 2.31, p = 0.52; $I^2 = 0\%$) (Fig 7).

Table 4. Main results for binary outcomes (Mantel-Haenszel method, random effect model).

| Outcome                        | Studies, n | Pooled RR (or ES) (95% CI) | p-value | $I^2$, % | $p_{heterogeneity}$ |
|--------------------------------|------------|----------------------------|---------|---------|--------------------|
| All-cause mortality            | 8          | 0.46 (0.28 to 0.77)        | 0.003   | 0.0     | 0.481              |
| Prescription duration          |            |                            |         |         |                    |
| ≤5d                            | 2          | 0.59 (0.24 to 1.43)        | 0.241   | 0.0     | 0.661              |
| >5d                            | 6          | 0.41 (0.21 to 0.82)        | 0.012   | 15.1    | 0.317              |
| Length of hospital stay        | 3          | -4.76 (-8.13 to -1.40)     | 0.006   | 43.4    | 0.170              |
| Length of ICU stay             | 5          | -1.84 (-4.23 to 0.56)      | 0.130   | 38.6    | 0.182              |
| Developed ARDS                 | 3          | 0.23 (0.07 to 0.80)        | 0.020   | 0.0     | 0.743              |
| Required mechanical ventilation| 4          | 0.50 (0.27 to 0.92)        | 0.026   | 0.0     | 0.841              |
| Adverse effects                |            |                            |         |         |                    |
| hyperglycemia                  | 3          | 1.03 (0.61 to 1.72)        | 0.91    | 0.0     | 0.385              |
| gastrointestinal hemorrhage    | 5          | 0.66 (0.19 to 2.31)        | 0.52    | 0.0     | 0.954              |

RR: risk ratio; ES: effect size; ICU: intensive care unit; ARDS: acute respiratory distress syndrome.

doi:10.1371/journal.pone.0165942.t004

Fig 2. Forest plots of the association between all-cause mortality of severe CAP and corticosteroids.
doi:10.1371/journal.pone.0165942.g002
Fig 3. Subgroup analysis according to the duration of corticosteroids treatment in severe CAP.
doi:10.1371/journal.pone.0165942.g003

Fig 4. Forest plots of the association between length of hospital stay and corticosteroids.
doi:10.1371/journal.pone.0165942.g004
Fig 5. Forest plots of the association between length of ICU stay and corticosteroids.
doi:10.1371/journal.pone.0165942.g005

Fig 6. Effect of corticosteroids on development of ARDS and need for mechanical ventilation in patients hospitalized with severe CAP.
doi:10.1371/journal.pone.0165942.g006
Sensitivity analysis and publication bias

A sensitivity analysis was implemented by the sequential dropping of each study. In above analyses, we just used this analytical method in length of hospital stay.

Considering the limited number (<10) of studies included, we did not evaluate publication bias in this systematic review.

Discussion

This systematic review and meta-analysis had included 8 RCTs, which evaluated the outcomes of adjunctive corticosteroids therapy in adult patients with severe CAP. The main results of meta-analysis were as follows: (1) corticosteroids reduced all-cause mortality for severe CAP; (2) prolonged corticosteroids therapy shortened length of hospital stay for severe CAP; (3) corticosteroids reduced the risk of ARDS and the need for mechanical ventilation. Additionally, our analysis demonstrated that the incidence of hyperglycemia was increased by systemic corticosteroids but the difference was not statistically significant.

In this meta-analysis, the results demonstrated a statistically significant decrease in the mortality of severe CAP patients treated with corticosteroids. We included all eligible trials with high quality and a low risk of bias except one study [26]. Usually, clinicians used adjunctive corticosteroids therapy for severe CAP especially in the early stage. And there are three
potential reasons for the survival advantage. First, corticosteroids are the most powerful inhibitor of inflammation which is part of the complex biological reaction to harmful stimuli such as trauma and pathogens. In addition, the pathogenesis of the majority of severe CAP is usually closely related with the excessive inflammatory response [50]. The anti-inflammatory mechanism of corticosteroids is not completely clear; however, it is believed that corticosteroids play an important role in switching on genes that encode anti-inflammatory cytokines and switching off genes that encode pro-inflammatory cytokines [10, 51]. And in a model of *Pseudomonas aeruginosa* with mechanical ventilation, the results showed that the treatment of antibiotics plus corticosteroids diminished the inflammatory response, decreased bacterial burden in lungs and improved the histopathological severity of pneumonia [52]. Second, the CIRCI was closely associated with severe CAP apart from the excessive inflammation. A systematic review revealed that severe CAP had a prevalence of CIRCI ranging from 0% to 48% [30], and the elevated cortisol levels could be a useful prognostic marker in patients with severe CAP [12]. Therefore, corticosteroids replacement therapy might be effective in severe CAP. Finally, corticosteroids could reduce the mortality of severe CAP for the reason of the reduction in the risk of ARDS and the need for mechanical ventilation [53].

The optimal corticosteroids regimens for severe CAP are not fully explored. The duration of corticosteroids treatment in those studies, which ranged from 1 to 9 days, was five days on average with a median of seven days. Horita et al. found that prolonged use of corticosteroids (>5 days) was not more effective than a short course (≤5 days). To the contrary, our results suggested that prolonged use of corticosteroids (>5 days) was more effective for severe CAP. It is noteworthy that the number of studies referred to the short course of corticosteroids was small (2 studies). Additionally, The optimal dosage of corticosteroids is also unclear. Most studies used hydrocortisone 200–300mg/day, prednisolone/methylprednisolone 20–50mg/day, or methylprednisolone 1mg/kg/day [35], which were so-called low-or middle-dose of corticosteroids and would be the most suitable dosage in clinical application. Therefore, physicians needed to adjust the dosage and duration of corticosteroids individually.

Our study demonstrated that prolonged use of corticosteroids (>5 days) decreased the length of hospital stay in severe CAP patients. At first, we estimated the result using the value of medians in 5 studies and found a strong heterogeneity ($I^2 = 90.6\%$). There were three main sources of heterogeneity: methodological heterogeneity, clinical heterogeneity and statistic heterogeneity [47]. In our study, heterogeneity mainly stemmed from methodological heterogeneity and clinical heterogeneity, so we conducted a subgroup analysis and sensitivity analysis. Subgroup analysis performed by duration of corticosteroids, the result was -5.79 days (95%CI: -8.17 to -2.31, $I^2 = 61.4\%$). Considering the study of Nafae with a high risk of bias, we performed a sensitivity analysis to exclude Nafae, and the final result was -4.76 days (95%CI: -8.13 to -1.40, $I^2 = 43.4$, p for heterogeneity = 0.17). Adjunctive corticosteroids therapy not only reduced the hospitalization time of severe CAP, but also alleviated the suffering of patients, and finally reduced the financial social-economic burdens [54]. In our study, the potential adverse effects of corticosteroids in severe CAP should be clarified. Theoretically, corticosteroids have the following adverse effects: metabolic disorders (mainly including hyperglycemia), muscle weakness, gastroduodenal bleeding and superinfection. A previous study showed that corticosteroids therapy increased the risks of hypernatremia and hyperglycemia [55]. In our meta-analysis, treatment with corticosteroids in severe CAP was associated with an increased risk of hyperglycemia but the difference had not statistically significant. However, we have not analyzed the association of corticosteroids and the risk of hypernatremia or superinfection, since sufficient information could not be extracted from primary publications. We considered rigorous and comprehensive studies should be designed.
Limitations of this study should be considered: (1) A small number of included studies and relatively small samples had significant influences on the reliability of the results. (2) The definition of severe CAP was not consistent in these studies. It is difficult to achieve a uniform diagnostic criteria due to individual differences in patient, the complex of disease, doctors’ subjective judgments and various severe CAP scoring systems. Therefore, diagnosis of severe CAP in clinical practices should be comprehensive, included demographic, clinical features plus radiographic, laboratory (some useful biochemical indicators), and microbiologic testing. (3) The optimal corticosteroids regimens for severe CAP were not fully clarified, which were associated with the differences in type, duration and dosage of corticosteroids, antibiotic therapy, and drug tapering course. (4) The detailed descriptions of severe CAP patients, such as a high inflammatory response, complications, and gender differences, were not fully clear.

In conclusions, our results suggested that adjunctive corticosteroids therapy decreased all-cause mortality in patients with severe CAP, and prolonged corticosteroids treatment was more beneficial for severe CAP. In addition, the study indicated that corticosteroids treatment was safe and reduced the risk of ARDS and the need for mechanical ventilation. Considering the limited number of severe CAP patients, the results may not be stabilized. Thus, large-scale, randomized, double-blind, placebo-controlled trials are needed to evaluate the efficacy and safety of adjunctive corticosteroids therapy in adults with severe CAP.

Supporting Information
S1 File. PRISMA Check List.
(PDF)
S2 File. Meta-analysis on genetic association studies checklist.
(DOCX)
S3 File. Detailed search strategy.
(DOCX)

Acknowledgments
This systematic review and meta-analysis was performed in the supports of Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University. We would like to express our deepest appreciation for all the members who help us to accomplish this study.

Author Contributions
Conceptualization: JB JY YW Y. Lu.
Data curation: JB JY.
Formal analysis: JB JY CY Y. Liu.
Funding acquisition: JY.
Investigation: JB JY YW.
Methodology: JB JY CY Y. Liu.
Project administration: JY Y. Lu.
Resources: JB JY YW.
Software: JB CY Y. Liu.
Supervision: YW JM.
Validation: JY JC Y. Liu.
Visualization: JY Y. Lu.
Writing – original draft: JB.
Writing – review & editing: JY JC Y. Lu.

References
1. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006; 10 Suppl 2:S1.
2. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013; 8(4):e60273. doi: 10.1371/journal.pone.0060273 PMID: 23565216
3. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014; 370(6):543–51. doi: 10.1056/NEJMcp1214869 PMID: 24499212
4. Alvarez-Lerma F, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care. 2004; 10(5):369–74. PMID: 15385753
5. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007; 35(6):1493–8. doi: 10.1097/01.CCM.0000266755.75844.05 PMID: 17452932
6. Mandell LA. Community-acquired pneumonia: An overview. Postgraduate medicine. 2015; 127(6):607–15. doi: 10.1080/00325481.2015.1074030 PMID: 26224210
7. Endeman H, Meijvis SC, Rijkers GT, van Velzen-Blad H, van Moorssel CH, Grutters JC, et al. Systemic cytokine response in patients with community-acquired pneumonia. The European respiratory journal. 2011; 37(6):1431–8. doi: 10.1183/09031936.00074410 PMID: 20884746
8. Martinez R, Menendez R, Reyes S, Polverino E, Cilloniz C, Martinez A, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. The European respiratory journal. 2011; 37(2):393–9. doi: 10.1183/09031936.00040710 PMID: 20595152
9. Aliberti S, Brambilla AM, Chalmers JD, Cilloniz C, Ramirez J, Bignamini A, et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory research. 2014; 15:27. doi: 10.1186/1465-9921-15-27 PMID: 24593040
10. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005; 353(16):1711–23. doi: 10.1056/NEJMra050541 PMID: 16236742
11. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Art W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008; 36(6):1937–49. doi: 10.1097/01.CCM.000031817603ba PMID: 18496365
12. Salluh JI, Verdeal JC, Mello GW, Araujo LV, Martins GA, de Sousa Santino M, et al. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med. 2006; 32(4):595–8. doi: 10.1007/s00134-005-0046-9 PMID: 16552616
13. Salluh JI, Bozza FA, Soares M, Verdeal JC, Castro-Faria-Neto HC, Lapa ESR, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008; 134(5):947–54. doi: 10.1378/chest.08-1382 PMID: 18753464
14. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. The European respiratory journal. 2015; 45(2):463–72. doi: 10.1183/09031936.00081514 PMID: 25323232
15. Wagner HN Jr., Bennett IL Jr., Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956; 98(3):197–215. PMID: 13304518
16. McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Br Med J. 1972; 4(5840):569–73. PMID: 4404939
17. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993; 104(2):389–92. PMID: 8339624

18. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005; 171(3):242–8. doi: 10.1164/rccm.200406-808OC PMID: 15557131

19. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone infusion in ICU patients with severe community-acquired pneumonia. Egyptian Journal of Chest. 2006; 55:91–9.

20. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007; 185(5):249–55. doi: 10.1007/s00408-007-9020-3 PMID: 17710485

21. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blind clinical trial. Am J Respir Crit Care Med. 2010; 181(9):975–82. doi: 10.1164/rccm.200905-0808OC PMID: 20133929

22. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Fernandez-Aguera A, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011; 15(2):R6. doi: 10.1186/cc10103 PMID: 21406101

23. Meijvis SC, Hardeman R, Remmeltz HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9782):2023–30. doi: 10.1016/S0140-6736(11)60607-7 PMID: 21636122

24. Sabry NA, Omar EE. Corticosteroids and ICU course of community-acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011; 2:73–81.

25. Remmeltz HH, Meijvis SC, Heijligenberg R, Rijkers GT, Oosterheert JJ, Bos WJ, et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect. 2012; 65(1):25–31. doi: 10.1016/j.jinf.2012.03.008 PMID: 22410382

26. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis. 2013; 62:439–45.

27. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977):1511–8. doi: 10.1016/S0140-6736(14)62447-8 PMID: 25608756

28. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. Jama. 2015; 313(7):677–86. doi: 10.1001/jama.2015.8855 PIDM: 25686779

29. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008; 62(4):661–8. doi: 10.1093/jac/dkn283 PMID: 18641037

30. Salluh JI, Shinotsuka CR, Soares M, Bozza FA, Lapadela Silva JR, Tura BR, et al. Cortisol levels and adrenal response in severe community-acquired pneumonia: a systematic review of the literature. J Crit Care. 2010; 25(3):541.e1–8.

31. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2011(3):CD007720. doi: 10.1002/14651858.CD007720.pub2 PMID: 21412908

32. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012; 7(10):e47926. doi: 10.1371/journal.pone.0047926 PMID: 23112872

33. Shafiq M, Mansoor MS, Khan AA, Sohail MR, Murad MH. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med. 2013; 8(2):68–75. doi: 10.1002/jhm.1992 PMID: 23184813

34. Gusmao-Flores D. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014; 59(8):e118.

35. Horita N, Otsuka T, Hanagasa S, Namkoong H, Miki M, Miyashita N, et al. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep. 2015; 5:14061. doi: 10.1038/srep14061 PMID: 26374694

36. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163(7):519–28. doi: 10.7326/M15-0715 PMID: 26258555
37. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest. 2016; 149(1):209–19. doi: 10.1378/chest.15-1733 PMID: 26501852

38. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377–82. doi: 10.1136/thorax.58.5.377 PMID: 12728155

39. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243–50. doi: 10.1056/NEJM199701233360402 PMID: 8995086

40. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27–72.

41. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001; 56 Suppl 4:Iv1–64.

42. Marti C, Garin N, Grosqurin O, Poncet A, Combesecure C, Carballo S, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012; 16(4):R141. doi: 10.1186/cc11447 PMID: 22839689

43. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008; 47(3):375–84. doi: 10.1086/589754 PMID: 18558844

44. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009; 37(2):456–62. doi: 10.1097/CCM.0b013e318194bb21 PMID: 19114916

45. Si8gl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013; 29(3):563–601. doi: 10.1016/j.ccc.2013.03.009 PMID: 23830654

46. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13. doi: 10.1186/1471-2288-5-13 PMID: 15840177

47. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Bmj. 2001; 323(7304):101–5. PMID: 11451790

48. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13. doi: 10.1186/1471-2288-5-13 PMID: 15840177

49. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care. 2010; 25(3):420–35. doi: 10.1016/j.jcrc.2009.08.009 PMID: 19896324

50. Carratala J, Garcia-Vidal C, Ortega L, Fernandez-Sabe N, Clemente M, Albero G, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012; 172(12):922–8. doi: 10.1001/archinternmed.2012.1690 PMID: 22732747

51. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Jama. 2009; 301(22):2362–75. doi: 10.1001/jama.2009.815 PMID: 19509383